NCT00492570

Brief Summary

This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
230

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2006

Typical duration for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2006

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

June 25, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 27, 2007

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2007

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
Last Updated

June 16, 2009

Status Verified

June 1, 2009

Enrollment Period

1.5 years

First QC Date

June 25, 2007

Last Update Submit

June 15, 2009

Conditions

Relapsing-Remitting Multiple Sclerosis

Keywords

Multiple SclerosisCognitive Dysfunction in Multiple sclerosisearly treatmentAvonexinterferon beta 1aCognitive Dysfunction

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

multi-center using 150-200 neurologists and their patient populations.

You may qualify if:

  • CIS (according to indication) or early Relapsing Remitting Multiple Sclerosis

You may not qualify if:

  • treatment with DMT during the last 12 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Multiple Sclerosis, Relapsing-RemittingMultiple SclerosisCognitive Dysfunction

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesCognition DisordersNeurocognitive DisordersMental Disorders

Study Officials

  • Biogen-Idec Study Director

    Biogen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

June 25, 2007

First Posted

June 27, 2007

Study Start

April 1, 2006

Primary Completion

October 1, 2007

Study Completion

December 1, 2008

Last Updated

June 16, 2009

Record last verified: 2009-06